Related Experiment Video

Updated: Aug 7, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Bortezomib for multiple myeloma

Rakesh Popat1, Simon Joel, Heather Oakervee

  • 1Department of Haematology, St. Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK. r.popat@qmul.ac.uk

Expert Opinion on Pharmacotherapy
|June 30, 2006
PubMed

Insights

The proteasome pathway regulates cell functions. Bortezomib, a proteasome inhibitor, effectively treats multiple myeloma by inducing cancer cell death, showing superiority over other treatments.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • The ubiquitin-proteasome pathway is crucial for cellular homeostasis, degrading proteins involved in cell cycle and apoptosis.
  • Malignant cells, with high proliferation and protein production, are particularly vulnerable to proteasome inhibition.
  • Bortezomib is approved for relapsed multiple myeloma, demonstrating efficacy and tolerability.

Purpose of the Study:

  • To review the pharmacology, toxicity, and clinical activity of bortezomib.
  • To highlight bortezomib's efficacy in multiple myeloma treatment.
  • To discuss its potential synergistic effects with other chemotherapeutic agents.

Main Methods:

  • Review of preclinical data on bortezomib's mechanism of action and efficacy.
  • Analysis of clinical trial results for bortezomib in multiple myeloma.
  • Evaluation of bortezomib's toxicity profile and therapeutic potential.

Main Results:

  • Bortezomib demonstrates efficacy and tolerability in relapsed multiple myeloma.
  • It shows superiority compared to high-dose dexamethasone.
  • Preclinical studies suggest synergy with other chemotherapeutic agents and potential to overcome drug resistance.

Conclusions:

  • Bortezomib is an effective treatment for relapsed multiple myeloma.
  • Its mechanism of action targets the ubiquitin-proteasome pathway, leading to cancer cell death.
  • Further combination studies are warranted to explore its full therapeutic potential.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...